Skip to content

Etomidate/Propofol Mixture or Propofol Monotherapy Use in Patients Undergoing General Anesthesia

Effects of Etomidate/Propofol Mixture or Propofol Monotherapy With Different Proportions on Circulation and Prognosis in Patients Undergoing General Anesthesia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03855267
Enrollment
200
Registered
2019-02-26
Start date
2019-01-01
Completion date
2019-12-01
Last updated
2019-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Etomidate is Mixed With Propofol

Keywords

propofol, etomidate, General anesthesia, mixture

Brief summary

The purpose of this study was to investigate the effects of different proportions of etomidate/propofol mixture and propofol alone intravenous anesthesia on intraoperative and postoperative physiological indicators and complications, and to find out the optimal use ratio of E/P mixture.

Detailed description

Propofol is one of the most commonly used intravenous anesthesia drugs clinically, the pharmacokinetic characteristics makes it very suitable for total intravenous anesthesia( TIVA), etomidate belongs to intravenous anesthesia with propofol, is a derivative of the imidazoles, its calm performance is strong, work quickly, no obvious respiratory depression, had little effects on the cardiovascular system, which, therefore, to protect the cardiovascular, maintain hemodynamic stability has a certain advantage. Our previous project showed that propofol and etomidate combined application can maintain stable hemodynamics in patients with better, reduce the occurrence of adverse reactions, can be used within 3 h of surgery anesthesia.The purpose of this study is to use propofol or etomidate/propofol mixture in combination with BIS monitoring to perform general anesthesia maintenance for patients, in order to ensure the appropriate depth of anesthesia, better maintain the hemodynamic stability of patients, reduce adverse reactions, and find the appropriate E/P mixture of the best proportion and dose.

Interventions

DRUGPropofol 20 MG/ML

Pump propofol to keep bispectral index within 40 # 60

DRUGPropofol 20 mg/ml , etomidate 2 mg/ml

Propofol was mixed with etomidate in different proportions.keep bispectral index within 40 # 60.

Sponsors

Guolin Wang
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Patients undergoing elective general anesthesia surgery in 3h; 2. American Society of Anesthesiologists gradesⅠ\ III; 3. Aged 18 to 65 years, Body Mass Index 18.5 \ 29.9kg / m2; 4. Hemoglobin 100 \ 125g / L. 5. In line with the ethics, the patients volunteered to take the test and signed the informed consent

Exclusion criteria

1. Identify or suspect abuse or chronic use of narcotic sedatives and analgesics; 2. Heart, or liver, or lung, or kidney dysfunction; 3. Body mass index\> 30kg / m2; or \<18.5kg / m2 4. Speech, hearing or mental disorders; 5. severe diabetes, hyperkalemia ; 6. participate in other drug clinical researches in four weeks; 7. Poor compliance, can not complete clinical research by research program. 8. Any cerebrovascular accident occurred within 3 months, such as stroke, TIA, etc 9. Unstable angina and myocardial infarction occurred within 3 months; 10. Having contraindications or allergies to experimental drugs and other narcotic drugs; 11. Mental illness, hyperkalemia.

Design outcomes

Primary

MeasureTime frameDescription
blood pressureintraoperativethe blood pressure is recorded (mmHg)
heart rateintraoperativethe heart rate is recorded(bpm)

Secondary

MeasureTime frameDescription
Perioperative complicationsintraoperativethe incidence of injection pain #nausea and vomit#intraoperative awareness and postoperative agitation.

Other

MeasureTime frameDescription
Recovery timeintraoperativeAnesthesia awakening time and extubation time

Countries

China

Contacts

Primary ContactZicheng Wang, MM
527640484@qq.com13821112922

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026